# OnCo record cmml (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/cmml/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "cmml" ;
  schema:name "Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms"@en ;
  schema:alternateName "CMML"@en, "MDS/MPN"@en, "Myelodysplastic/myeloproliferative neoplasms"@en, "Atypical CML (BCR-ABL1-negative)"@en, "MDS/MPN with ring sideroblasts and thrombocytosis"@en, "MDS/MPN with SF3B1 mutation and thrombocytosis"@en, "Juvenile myelomonocytic leukaemia (JMML)"@en ;
  schema:description "Chronic myelomonocytic leukaemia and its relatives are bone-marrow cancers that behave partly like myelodysplasia (poorly made blood cells) and partly like a proliferative disease (an excess of monocytes or platelets). Hypomethylating agents produce responses in a minority and stabilise counts in more, transplant can cure the fit, and RAS-pathway and JAK inhibitors are in trials."@en ;
  schema:url <https://onco.cc/cancers/cmml/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Chronic_myelomonocytic_leukemia> ;
  schema:citation <https://www.cancer.gov/types/myeloproliferative/patient/mds-mpn-treatment-pdq>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1446>, <https://doi.org/10.1038/s41375-022-01613-1>, <https://doi.org/10.1182/blood.V88.7.2480.bloodjournal8872480> ;
  onco:tag "nci-coverage", "rare", "haematologic" ;
  onco:related <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/myeloproliferative-neoplasms/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/cml/>, <https://onco.cc/cancers/systemic-mastocytosis/>, <https://onco.cc/cancers/cll/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/cytogenetics-fish/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/ngs-bioinformatics-software/>, <https://onco.cc/technologies/transfusion-support/> ;
  onco:targets <https://onco.cc/targets/jak2/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/bcl2/> ;
  onco:drugs <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/decitabine-cedazuridine/>, <https://onco.cc/drugs/hydroxyurea/>, <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/luspatercept/>, <https://onco.cc/drugs/lenzilumab/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/jak-stat/>, <https://onco.cc/pathways/epigenetic-reprogramming/>, <https://onco.cc/pathways/clonal-haematopoiesis/>, <https://onco.cc/pathways/rna-splicing/> ;
  onco:terms <https://onco.cc/terms/hma/>, <https://onco.cc/terms/blasts/>, <https://onco.cc/terms/cytopenias/>, <https://onco.cc/terms/cytogenetics/>, <https://onco.cc/terms/conditioning-regimen/> ;
  onco:trials <https://onco.cc/trials/nct04256317/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-aging-comorbidity/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-wattel-blood/> ;
  onco:pipeline <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/jbi-802/>, <https://onco.cc/drugs/tuspetinib/>, <https://onco.cc/drugs/bexmarilimab/> ;
  onco:standardOfCare <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/decitabine-cedazuridine/>, <https://onco.cc/terms/hma/>, <https://onco.cc/technologies/transfusion-support/>, <https://onco.cc/drugs/hydroxyurea/>, <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/technologies/allogeneic-hsct/> .